BioMarin joined a group seeking to scale enzyme-based production of therapeutic oligonucleotides and cut waste and costs. No company-specific savings, sales, or products are reported, so its outlook is unchanged.
The work could make RNA-medicine production cheaper and easier to expand. The story reports goals, not completed changes, and gives no BioMarin product, sales, or cost results. Its business outlook therefore remains unchanged.
AstraZeneca joined the production collaboration, which aims to cut waste and costs. The story reports no company-specific savings, sales, or product changes, so its outlook is unchanged.
Novo Nordisk joined the production collaboration, which aims to cut waste and costs. The story reports no company-specific savings, sales, or product changes, so its outlook is unchanged.
Novartis joined the production collaboration, which aims to cut waste and costs. The story reports no company-specific savings, sales, or product changes, so its outlook is unchanged.
Get alerts for BMRN
Follow BioMarin Pharmaceutical Inc. (BMRN) free. When we publish a story about it, you get the plain-English explanation as an alert.